JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Albuterol is a research compound studied in cell-based assay formats for its selective beta-2 adrenergic receptor (beta-2 AR) Gs/cAMP pathway agonism. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions.
Albuterol acts via selective beta-2 adrenergic receptor (beta-2 AR) Gs/cAMP pathway agonism. Competitive radioligand binding assays demonstrate preferential affinity for beta-2 AR subtypes compared to beta-1 and beta-3 variants. In vitro binding studies utilising [³H]-dihydroalprenolol displacement methodology reveal Ki values ranging from 0.1-1.0 μM for beta-2 AR, with significantly reduced affinity for beta-1 adrenergic receptors.
Upon receptor engagement, albuterol initiates Gs-protein activation, leading to adenylyl cyclase stimulation and subsequent cyclic adenosine monophosphate (cAMP) accumulation. Forskolin-stimulated cAMP assays in transfected cell lines demonstrate dose-dependent increases in intracellular cAMP levels, with EC₅₀ values typically observed between 10-100 nM in optimised assay conditions.
Research applications utilise primary human bronchial epithelial cells (HBECs) and immortalised cell lines including BEAS-2B and 16HBE14o- models. These cellular systems express endogenous beta-2 adrenergic receptors and maintain physiologically relevant signalling machinery for mechanistic investigations.
Human airway smooth muscle cells (HASMCs) serve as complementary research tools, expressing high-density beta-2 AR populations. Contractility assays measuring isometric tension responses provide functional readouts for receptor activation and downstream effector engagement.
Elevated cAMP levels activate protein kinase A (PKA), initiating phosphorylation cascades affecting multiple downstream targets. Western blot analyses demonstrate PKA-mediated phosphorylation of cAMP response element-binding protein (CREB) at serine-133, enabling transcriptional regulation of target genes.
Beta-2 AR activation influences intracellular calcium homeostasis through multiple mechanisms. Fluorescent calcium imaging studies reveal reduced calcium mobilisation in response to contractile stimuli, mediated by PKA-dependent phosphorylation of calcium-handling proteins including phospholamban and myosin light chain kinase.
Research demonstrates beta-2 AR-mediated modulation of various ion channels, particularly large-conductance calcium-activated potassium (BKCa) channels. Patch-clamp electrophysiology studies show enhanced BKCa channel activity following cAMP elevation, contributing to membrane hyperpolarisation effects.
Kinetic binding studies reveal rapid association rates (kon) of approximately 10⁷ M⁻¹s⁻¹ and dissociation rates (koff) around 10⁻² s⁻¹, yielding equilibrium dissociation constants in the nanomolar range. Saturation binding experiments demonstrate Bmax values correlating with receptor expression levels across different cell model systems.
Enzyme kinetic analyses of adenylyl cyclase activation show Michaelis-Menten behaviour with Km values for ATP substrate utilisation remaining consistent across treatment conditions. Maximum velocity (Vmax) parameters increase proportionally with receptor occupancy, indicating efficient G-protein coupling.
Time-resolved fluorescence resonance energy transfer (TR-FRET) based cAMP detection methods enable high-throughput screening applications. These assays demonstrate concentration-dependent responses with typical Hill coefficients between 0.8-1.2, indicating classical receptor occupancy relationships.
PKA activity assays utilising synthetic peptide substrates (Kemptide) provide quantitative measures of downstream signalling activation. Radiometric and fluorescence-based detection methods show dose-dependent increases in kinase activity correlating with upstream cAMP generation.
In vitro pharmacological characterisation of albuterol reveals selective beta-2 adrenergic receptor agonism with high binding affinity and efficient G-protein coupling. Cell-based assay systems demonstrate robust cAMP signalling pathway activation, with downstream effects on protein kinase A, calcium homeostasis, and ion channel function. These cellular model systems provide valuable research tools for investigating beta-2 adrenergic receptor pharmacology and associated signalling mechanisms in controlled laboratory environments. The compound's well-characterised receptor selectivity profile and signalling pathway engagement make it a useful reference standard for comparative pharmacological studies and mechanism-based research applications.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.